drugset / Trial / NCT01518387

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

NCT01518387

Phase 3 Completed 43 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.

Timeline

Start
2006-01
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanthanum Carbonate Other / unclassified

Indications